ArticleGenome biology2026
Glycoproteomic and genetic analysis of N-glycosylation of complement component C3 reveals immune pathway regulation.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPost-translational modifications represent a critical layer of protein regulation, yet their genetic control and population variation remain poorly characterized. Here we present a comprehensive analysis integrating population-scale glycoproteomics with genome-wide association study (GWAS) to uncover genetic regulatory networks controlling N-glycosylation of complement component C3.
resultsThrough LC-MS glycopeptide analysis of 816 Croatian adults, we characterize site-specific N-glycosylation at two C3 sites (N63 and N917), confirming an unusual phenotype consisting of exclusive high-mannose structures rather than complex glycans typical of secreted proteins. GWAS identifies six genetic loci significantly associated with C3 N-glycosylation patterns, including genes encoding proteins involved in maintenance of the protein secretory pathway, proteins involved in the complement pathway or regulation of complement, and regulators of gene expression. Using colocalization analysis, we discover shared causal variants between C3 glycosylation and immune diseases, particularly rheumatoid arthritis and inflammatory bowel disease, suggesting glycosylation as a mechanistic link between genetic variation and disease susceptibility. C3 N-glycoprofiling reveals significant associations with sex, age, and metabolic parameters, indicating integration of genetic and environmental factors. Structural modeling provides mechanistic insights, revealing how protein architecture constrains glycan processing and enables functional glycan-mediated interactions.
conclusionsOur multiomic approach establishes a framework for understanding how genetic variation shapes post-translational modifications at population scale, demonstrating C3 N-glycosylation as both a genetically and environmentally regulated checkpoint in complement activation with implications for precision medicine approaches in immune and metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.